Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum

被引:33
|
作者
Subehan
Usia, Tepy
Kadota, Shigetoshi
Tezuka, Yasuhiro [1 ]
机构
[1] Toyama Univ, Inst Nat Med, Toyama 9300194, Japan
[2] Toyama Univ, 21st Century COE Program, Toyama 9300194, Japan
关键词
Piper nigrum; alkamides; cytochrome P450 2D6; CYP2D6; mechanism-based inhibition; drug-herb interaction;
D O I
10.1055/s-2006-931558
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Nineteen alkamides isolated from Piper nigrum L. were tested for their mechanism-based inhibition on human liver microsomal dextromethorphan O-demethylation activity, a prototype marker for cytochrome P450 2D6 (CYP2D6). All compounds increased their inhibitory activity with increasing preincubation time. Among them, 15 and 17 showed more than 50% decrease of the CYP2D6 residual activity after 20 min preincubation. Further investigations on 15 and 17 showed that the characteristic time and concentration-dependent inhibition, which required a catalytic step with NADPH, was not protected by nucleophiles, and was decreased by the presence of a competitive inhibitor. The kinetic. parameters for inactivation (k(inact) and k(I)) were 0.028 min(-1) and 0.23 mu M for 15 and 0.064 min(-1) and 0.71 mu M for 17, respectively, which were stronger than the known mechanism-based inhibitor, paroxetine (a positive control). Thus, 15 and 17 are potent mechanism-based inhibitors of CYP2D6.
引用
收藏
页码:527 / 532
页数:6
相关论文
共 50 条
  • [41] Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR
    Bodin, L
    Beaune, PH
    Loriot, MA
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2005, (03): : 248 - 253
  • [42] Cytochrome P450 2D6 as a Model Antigen
    Christen, Urs
    Holdener, Martin
    Hintermann, Edith
    DIGESTIVE DISEASES, 2010, 28 (01) : 80 - 85
  • [43] The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)
    Rodrigues, AD
    Roberts, EM
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (05) : 651 - 655
  • [44] Allosteric effects of cytochrome P450 reductase on cytochrome P450 2D6
    Roberts, GCK
    Modi, S
    Gilham, DE
    Sutcliffe, MJ
    Lian, LY
    Primrose, WU
    Wolf, CR
    FASEB JOURNAL, 1997, 11 (09): : A789 - A789
  • [45] Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6
    Song, Min
    Hong, Miri
    Lee, Min Young
    Jee, Jun-Goo
    Lee, You Mie
    Bae, Jong-Sup
    Jeong, Tae Cheon
    Lee, Sangkyu
    FOOD AND CHEMICAL TOXICOLOGY, 2013, 59 : 549 - 553
  • [46] Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate
    McConnachie, L
    Bodor, M
    Kowdley, K
    Levy, A
    Tung, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DA
    Ho, RJY
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (04) : 282 - 297
  • [47] The CYP2D6 mouse model for autoimmune liver disease: Mapping of cytochrome P450 2D6 T cell epitopes in mice with autoimmune hepatitis
    Holdener, M.
    Hintermann, E.
    Bayer, M.
    Manns, M. P.
    von Herrath, M. G.
    Christen, U.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 40 - 40
  • [48] A refilled substrate model for human cytochrome P450 2D6
    deGroot, MJ
    Bijloo, GJ
    Martens, BJ
    vanAcker, FAA
    Vermeulen, NPE
    CHEMICAL RESEARCH IN TOXICOLOGY, 1997, 10 (01) : 41 - 48
  • [49] Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen
    Dong, HJ
    Haining, RL
    Thummel, KE
    Rettie, AE
    Nelson, SD
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (12) : 1397 - 1400
  • [50] Inhibitory monoclonal antibodies to human cytochrome P450 2D6
    Krausz, KW
    Yang, TJ
    Gonzalez, FJ
    Shou, MG
    Gelboin, HV
    BIOCHEMICAL PHARMACOLOGY, 1997, 54 (01) : 15 - 17